- Home
- PSMT vs EWTX Comparison
PSMT vs EWTX Comparison
Compare PSMT & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSMT | EWTX |
|---|---|---|
| Founded | 1994 | 2017 |
| Country | United States | United States |
| Employees | N/A | 127 |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 4.9B |
| IPO Year | 2005 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PSMT | EWTX |
|---|---|---|
| Price | $174.22 | $40.81 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $39.00 |
| AVG Volume (30 Days) | 173.0K | ★ 1.2M |
| Earning Date | 04-08-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.91% | N/A |
| EPS Growth | ★ 5.47 | N/A |
| EPS | ★ 4.18 | N/A |
| Revenue | ★ $4,066,093,000.00 | N/A |
| Revenue This Year | $12.29 | N/A |
| Revenue Next Year | $10.70 | N/A |
| P/E Ratio | $41.30 | ★ N/A |
| Revenue Growth | ★ 12.33 | N/A |
| 52 Week Low | $111.68 | $14.25 |
| 52 Week High | $199.84 | $48.51 |
Technical Indicators
Market Signals| Indicator | PSMT | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.29 | 41.08 |
| Support Level | $166.57 | $37.50 |
| Resistance Level | $180.37 | $41.04 |
| Average True Range (ATR) | 3.43 | 2.04 |
| MACD | 0.84 | -0.36 |
| Stochastic Oscillator | 57.76 | 13.56 |
Price Performance
Historical ComparisonAbout PSMT PriceSmart Inc.
Pricesmart Inc is principally engaged in operating U.S.-style membership shopping warehouse clubs that offer consumer goods at low prices. The company is headquartered in San Diego, California, United States, and operates stores in the Caribbean, Costa Rica, Panama, and other regions. The company's revenue consists of net warehouse club sales from merchandise sales, membership income from annual membership fees, export sales, and other income. Its operations consist of four reportable segments; Central America, the Caribbean, Colombia, and the United States. A majority of the company's revenue is derived from Central America.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.